Kuwait Life Sciences Company
Kuwait Life Sciences (KLSC) was established in 2010, with a paid up capital of 15 million Kuwait Dinars (KD) which is equivalent to approximately $53 million US Dollars. KLSC is fully owned by National Technology Enterprises Company. National Technology Enterprises Company (NTEC) was incorporated in November of 2002, by the Kuwait Council of Ministers as a fully owned company by the Kuwait Investment Authority (KIA), the sovereign wealth fund of the State of Kuwait. Capitalized at 100 million Kuwait Dinars (KD) which is equivalent to approximately $350 million US Dollars, NTEC aims to play a vital role in servicing major stakeholders in Kuwait and the Middle East region with their technology requirements. KLSC focuses on healthcare innovative concepts and demanded services which have a clear and unmet need in the Middle East and North Africa (MENA) region. KLSC has been designed as an integrated healthcare company building unique projects and is considered one of the pioneer venture capitalist and private equity companies in the Middle East that invests globally and operates regionally seeking to advance healthcare services and systems within the region. KLSC supports both public and private sector stakeholders to access emerging technologies, establish unique projects and adapt best practices prevailing in today’s healthcare field. KLSC operates in healthcare investment, life sciences training, medical technology and pharmaceutical distribution. Investment Strategy KLSC follows a similar investment strategy according to its parent company, NTEC, focusing on the following three pillars – 1) Incubation (Start Up) Projects – Local and Regional 2) Venture Capital – International 3) Private Equity – Regional and International Incubation (Start Up) Projects – Local and Regional KLSC invests in the project’s equity in partnership with the private sector entrepreneur or company and accommodates KLSC’s main strategic goal of technology transfer into Kuwait and the MENA region. These projects are internally developed by KLSC and externally developed by the private sector. In both cases, KLSC usually favors the formation of a Joint Venture, partnering with technology providers, supporting projects that add value, meet a local or regional demand and are an internationally proven concept. Examples already developed by KLSC include: Life Sciences Academy – a knowledge transfer platform Innomedics – a medical devices commercialization platform Newbridges – a pharmaceutical commercialization platform Venture Capital – International KLSC invest in companies with products or services which solve existing customer problems with ground-breaking technologies and have the potential for above average, substantial growth. Through many years of experience in direct venture capital investments and investing in world class venture capital funds, KLSC has developed a systematic process based on proprietary thought selection, comprehensive due diligence, and an active investment management. The focus is pre-commercialization stage companies that are viable and financially attractive with clear exit strategies and a vision to expand into new markets such as Kuwait and the MENA region. Examples of investments by KLSC include: Quanta Fluid Solutions – a market leader in (home) hemodialysis solutions Supersonic Imagine – a market leader in ultrasound imaging Median Technologies – a market leader in oncology monitoring and imaging Private Equity – Regional and International KLSC also invests in more established companies with the purpose of reducing the time gap of certain in-demand technology introduction into the mass markets that follow the existing technology transfer platforms identified by KLSC for the Life Sciences Industry. KLSC invests in the form of private equity in established life science and healthcare companies that have the potential of regional expansion, and a proven concept with sustainable business model. Examples of investments by KLSC include: Clinart – a clinical research (contract resource organization) platform eCore – an industrial (specialty chemicals) platform
Quanta is a medical devices company that develops advanced haemodialysis systems for use in the home and clinic. Quanta is focused on the commercialisation and ongoing development of SC+, an innovative cartridge-based haemodialysis system. SC+ is a high performance, compact haemodialysis system providing clinical efficacy by utilising typical flow rates of traditional in-centre machines. SC+ supports the entire ‘Continuum of Care’ for dialysis patients, from nurse-assisted treatment through self-care in centre to home haemodialysis. Their system facilitates the seamless transition between treatment modalities providing the best tool to enable flexibility for patients, and treatment options for physicians.
NewBridge Pharmaceuticals Ltd. is a specialty therapeutics company based in Dubai, United Arab Emirates, that focuses on pharmaceuticals, biologics, and medical diagnostics. Established in 2007, the company specializes in in-licensing and commercializing healthcare products to meet the unmet medical needs of patients in the Middle East, Africa, Turkey, and the Caspian regions. NewBridge offers a range of oncology and supportive care products, including Abstral for cancer pain management, Clasteon for bone metastasis-related conditions, Sancuso for chemotherapy-induced nausea, and Oncotype DX for breast cancer recurrence assessment. Additionally, it provides metabolic care products like Gliconorm for diabetes treatment and PYLERA for H. pylori eradication. The company's portfolio further includes CNS care products like Vimpat for seizures and Neupro for Parkinson's disease, as well as immunology care products such as Cimzia for rheumatoid arthritis. By addressing critical health issues such as cancer, diabetes, and cardiovascular diseases, NewBridge Pharmaceuticals aims to enhance patient care in its targeted regions.
Private Equity Round in 2013
SuperSonic Imagine SA is a medical technology company that specializes in developing and manufacturing advanced ultrasound imaging systems. Founded in 2005 and headquartered in Aix-en-Provence, France, the company is renowned for its Aixplorer system, which provides high-definition imaging and is particularly effective in diagnosing and monitoring breast, prostate, and thyroid cancers, as well as liver diseases. The Aixplorer system incorporates ShearWave technology, enabling quantitative elastography that measures tissue elasticity. SuperSonic Imagine operates primarily in markets such as China, the United States, and various European countries, distributing its products through a network of offices and distributors. As a subsidiary of Hologic Hub Ltd, the company continues to innovate in the field of medical imaging, enhancing the capabilities of healthcare professionals.
NewBridge Pharmaceuticals Ltd. is a specialty therapeutics company based in Dubai, United Arab Emirates, that focuses on pharmaceuticals, biologics, and medical diagnostics. Established in 2007, the company specializes in in-licensing and commercializing healthcare products to meet the unmet medical needs of patients in the Middle East, Africa, Turkey, and the Caspian regions. NewBridge offers a range of oncology and supportive care products, including Abstral for cancer pain management, Clasteon for bone metastasis-related conditions, Sancuso for chemotherapy-induced nausea, and Oncotype DX for breast cancer recurrence assessment. Additionally, it provides metabolic care products like Gliconorm for diabetes treatment and PYLERA for H. pylori eradication. The company's portfolio further includes CNS care products like Vimpat for seizures and Neupro for Parkinson's disease, as well as immunology care products such as Cimzia for rheumatoid arthritis. By addressing critical health issues such as cancer, diabetes, and cardiovascular diseases, NewBridge Pharmaceuticals aims to enhance patient care in its targeted regions.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.